Jon intimated in the PHS webinar an announcement about the undisclosed indications was months away (from May) so I think they will come out after the FDA meeting at the end of this quarter. To me, it would seem likely they will be announced in tandem with what their trial pathway is. Combine this with how Phase 3 will progress and you will know exactly what Neuren holds.
If the FDA meeting is successful I think things will move quickly.
Jon intimated in the PHS webinar an announcement about the...
-
- There are more pages in this discussion • 65 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.07 |
Change
-0.400(2.76%) |
Mkt cap ! $1.798B | |||
| Open | High | Low | Value | Volume |
| $14.47 | $14.53 | $13.99 | $7.843M | 552.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2150 | $14.06 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.10 | 1129 | 2 |
View Market Depth
| Last trade - 16.10pm 03/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |